Anavex Life Sciences Corp.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report0 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Anavex Life Sciences Corp.
1.15
pre 1.20 0.00%
+14.47%
vs ±24.1% implied · ×0.60
shaded = implied · ▲▼ = realized
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $20.9M | 21.18% | +5.86% |
| Vanguardindex-like | $10.5M | 10.66% | +4.93% |
| Two Sigma | $7.9M | 8.01% | −6.20% |
| Geodeindex-like | $6.2M | 6.33% | +10.02% |
| State Streetindex-like | $5.0M | 5.06% | −57.39% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $20.9M | 21.18% | +5.86% |
| Vanguardindex-like | $10.5M | 10.66% | +4.93% |
| Two Sigma | $7.9M | 8.01% | −6.20% |
| Geodeindex-like | $6.2M | 6.33% | +10.02% |
| State Streetindex-like | $5.0M | 5.06% | −57.39% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Anavex Life Sciences Corp.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Anavex Life Sciences Corp.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Nov 25 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Nov 25 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Tall tick = annual report · Source: EDGAR
Bull2
Bear1
Expected move
Inputsspot 1.20exp Dec 18ATM strike 1ATM straddle 0.50IV 156%